Jaguar Animal Health Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $6.31 million
- Book Value:
- Revenue TTM:
- $11.06 million
- Operating Margin TTM:
- Gross Profit TTM:
- $2.00 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Jaguar Animal Health Inc had its IPO on 2015-05-13 under the ticker symbol JAGX.
The company operates in the Healthcare sector and Biotechnology industry. Jaguar Animal Health Inc has a staff strength of 60 employees.
Shares of Jaguar Animal Health Inc opened at $0.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.32 - $0.34, and closed at $0.34.
This is a +2.7% increase from the previous day's closing price.
A total volume of 446,275 shares were traded at the close of the day’s session.
In the last one week, shares of Jaguar Animal Health Inc have slipped by -10.11%.
Jaguar Animal Health Inc's Key Ratios
Jaguar Animal Health Inc has a market cap of $6.31 million, indicating a price to book ratio of 4.6525 and a price to sales ratio of 1.5423.
In the last 12-months Jaguar Animal Health Inc’s revenue was $11.06 million with a gross profit of $2.00 million and an EBITDA of $-32125000. The EBITDA ratio measures Jaguar Animal Health Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Jaguar Animal Health Inc’s operating margin was -308.64% while its return on assets stood at -41.8% with a return of equity of -1060.66%.
In Q2, Jaguar Animal Health Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 8.4%.
Jaguar Animal Health Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-7.81 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.02. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Jaguar Animal Health Inc’s profitability.
Jaguar Animal Health Inc stock is trading at a EV to sales ratio of 3.6475 and a EV to EBITDA ratio of -0.9878. Its price to sales ratio in the trailing 12-months stood at 1.5423.
Jaguar Animal Health Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $52.17 million
- Total Liabilities
- $29.00 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Jaguar Animal Health Inc ended 2023 with $52.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $52.17 million while shareholder equity stood at $5.64 million.
Jaguar Animal Health Inc ended 2023 with $0 in deferred long-term liabilities, $29.00 million in other current liabilities, 1000.00 in common stock, $-291300000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.63 million and cash and short-term investments were $8.63 million. The company’s total short-term debt was $14,322,000 while long-term debt stood at $16.85 million.
Jaguar Animal Health Inc’s total current assets stands at $28.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.56 million compared to accounts payable of $4.66 million and inventory worth $8.26 million.
In 2023, Jaguar Animal Health Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Jaguar Animal Health Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Jaguar Animal Health Inc stock is currently trading at $0.34 per share. It touched a 52-week high of $19.2825 and a 52-week low of $19.2825. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $0.51 and 200-day moving average was $2.46 The short ratio stood at 0.7 indicating a short percent outstanding of 0%.
Around 1766.8% of the company’s stock are held by insiders while 204.9% are held by institutions.
Frequently Asked Questions About Jaguar Animal Health Inc
Similar Industry Stocks (Biotechnology)
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.